Steroid hormone receptor and COX-2 expression in chordoma

American Journal of Clinical Pathology

Volumn 128, Issue 3, 2007, Pages 375-381

  Fasig, John H ^a   Dupont, William D ^a   Olson, Sandra J ^a   LaFleur, Bonnie J ^a   Cates, Justin M M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Chordoma; COX 2; Cyclooxygenase 2; Estrogen receptor; Steroid hormone receptors

Indexed keywords

ANDROGEN RECEPTOR; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; CHORDOMA; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR LOCALIZATION;

ADULT; AGED; CHORDOMA; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SACRUM; SKULL NEOPLASMS; SPINAL NEOPLASMS;

EID: 34748874233     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/8T2NPHLK5X5WQ3E7     Document Type: Article

References (47)

1. Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597-3604.
2. Jacob HE. Chemotherapy for cranial base tumors. J Neurooncol. 1994;20:327-335.
3. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003;10:291-296.
4. Colli B, Al-Mefty O. Chordomas of the craniocervical junction: follow-up review and prognostic factors. J Neurosurg. 2001;95:933-943.
5. Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am. 2000;11:627-638.
6. Noel G, Habrand JL, Jauffret E, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine: prognostic factors and patterns of failure. Strahlenther Onkol. 2003;179:241-248.
7. York JE, Kaczaraj A, Abi-Said D, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74-79.
8. Dorfman HD, Czerniak B. Chordoma and related lesions. In: Bone Tumors. St Louis, MO: Mosby; 1998:974-1008.
9. Mirra JM, Nelson SD, Della Rocca C, et al. Chordoma. In: Fletcher CDM, Unni KK, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002:316-317. World Health Organization Classification of Tumours.
10. Berven S, Zurakowski D, Mankin HJ, et al. Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine. 2002;27:374-379.
11. Eriksson B, Gunterberg B, Kindblom LG. Chordoma: a clinicopathologic and prognostic study of a Swedish national series. Acta Orthop Scand. 1981;52:49-58.
12. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001;12:1-11.
13. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203-210.
14. Austin-Seymour M, Munzenrider J, Goitein M, et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg. 1989;70:13-17.
15. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999;175(suppl 2):57-63.
16. O'Connell JX, Renard LG, Liebsch NJ, et al. Base of skull chordoma: a correlative study of histologic and clinical features of 62 cases. Cancer. 1994;74:2261-2267.
17. Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys. 1999;45:351-358.
18. Castro JR, Linstadt DE, Bahary JP, et al. Experience in charged particle irradiation of tumors of the skull base, 1977-1992. Int J Radiat Oncol Biol Phys. 1994;29:647-655.
19. Rosenberg AE, Brown GA, Bhan AK, et al. Chondroid chordoma: a variant of chordoma: a morphologic and immunohistochemical study. Am J Clin Pathol. 1994;101:36-41.
20. Rosenberg AE, Nielsen GP, Keel SB, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol. 1999;23:1370-1378.
21. Halperin EC. Why is female sex an independent predictor of shortened overall survival after proton/photon radiation therapy for skull base chordomas? Int J Radiat Oncol Biol Phys. 1997;38:225-230.
22. Camacho-Arroyo I, Gonzalez-Aguero G, Gamboa-Dominguez A, et al. Progesterone receptor isoforms expression pattern in human chordomas. J Neurooncol. 2000;49:1-7.
23. Martinez R, Marcos ML, Figueras A, et al. Estrogen and progesterone receptors in intracranial tumors. Clin Neuropharmacol. 1984;7:338-342.
24. Romic Stojkovic R, Jovancevic M, Santel DJ, et al. Sex steroid receptors in intracranial tumors. Cancer. 1990;65:1968-1970.
25. Dannenberg AJ, DuBois RN. COX-2: a new target for cancer prevention and treatment. In: Progress in Experimental Tumor Research. Vol 37. New York, NY: Karger; 2003.
26. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431-502.
27. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001;8:97-114.
28. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206.
29. Kilgore S, Prayson RA. Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol. 2002;6:222-228.
30. Matsuno A, Sasaki T, Nagashima T, et al. Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas. Hum Pathol. 1997;28:714-719.
31. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086-2097.
32. Tamborini E, Miselli F, Negri T, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 2006;12:6920-6928.
33. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res. 2005;11:8028-8035.
34. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006;27:299-402.
35. Koehler KF, Helguero LA, Haldosen LA, et al. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev. 2005;26:465-478.
36. Pettetsson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001;63:165-192.
37. Giguere V, Tremblay A, Tremblay GB. Estrogen receptor beta: re-evaluation of estrogen and antiestrogen signaling. Steroids. 1998;63:335-339.
38. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81:1535-1565.
39. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol. 2004;50:3-22.
40. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000;24:145-155.
41. Acconcia F, Totta P, Ogawa S, et al. Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling. J Cell Physiol. 2005;203:193-201.
42. Imamov O, Shim GJ, Warner M, et al. Estrogen receptor beta in health and disease. Biol Reprod. 2005;73:866-871.
43. Brueggemeier RW, Richards JA, Joomprabutra S, et al. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J Steroid Biochem Mol Biol. 2001;79:75-84.
44. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100:612-620.
45. Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg. 1991;161:416-421.
46. Matsuda T, Junicho A, Yamamoto T, et al. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun. 2001;283:179-187.
47. Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. J Mol Med. 1998;76:469-479.